Royal Bank of Canada
NBIX icon

Royal Bank of Canada’s Neurocrine Biosciences NBIX Stock Holding History

Royal Bank of Canada’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-139,000
Closed -$1.86M – 6200
2013
Q2 		$1.86M Buy
+139,000
New +$1.71M ﹤0.01% 2111

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada's NBIX Position: Q1 2026 in Review

Royal Bank of Canada increased its Neurocrine Biosciences (NBIX) stake by 6.8% in Q1 2026, buying an estimated $2.82M and bringing the position to 332,300 shares worth $43.8M. The position accounts for 0.01% of the portfolio, ranked #981.

Royal Bank of Canada first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $44.1M in Q4 2025. 696 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Royal Bank of Canada held 332,300 shares of Neurocrine Biosciences worth $43.8M as of Q1 2026.
  • Royal Bank of Canada bought 21,288 Neurocrine Biosciences shares in Q1 2026, an estimated $2.82M.
  • Neurocrine Biosciences made up 0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #981 holding.
  • Royal Bank of Canada first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Neurocrine Biosciences position peaked at $44.1M in Q4 2025.
  • 696 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.